Clinical Trial Update: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologically suppressed patients from regimens containing ABC/3TC plus a third agent to the fixed-dose combination elvitegra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-07-13